Phase
Condition
Metabolic Syndrome
High Cholesterol (Hyperlipidemia)
Diabetes Prevention
Treatment
High Intensity Exercise + Placebo
Low Intensity Exercise + Placebo
Low Intensity Exercise + Metformin
Clinical Study ID
Ages 40-70 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
Male or female >40 and <70 years old.
Has a body mass index >27 and <47 kg/m2.
Not diagnosed with Type 2 diabetes.
Not currently engaged in > 60 min/wk of exercise
Meet at least 3 of 5 National Cholesterol Education Adult Treatment Panel III
Metabolic Syndrome criteria:
Increased waist circumference (≥102 cm in men; ≥88 cm in women)
Elevated triglycerides (≥150 mg/dl), or on medication for treating the condition
Reduced HDL-cholesterol (<40mg/dl in men, <50 mg/dl in women), or on medication fortreating the condition
High blood pressure (≥130 mmHg systolic or ≥85mmHg diastolic), or on medication fortreating the condition
Elevated fasting glucose (≥100 mg/dl), or on medication for treating the condition
Exclusion
Exclusion Criteria:
Morbidly obese patients (BMI >47 kg/m2) and overweight/lean patients (BMI <27 kg/m2)
Evidence of type 1 diabetes and diabetics requiring insulin therapy.
Subjects who have not been weight stable (>2 kg weight change in past 3 months)
Subjects who have been recently active (>30 min of moderate/high intensity exercise, 2 times/week).
Subjects who are smokers or who have quit smoking <5 years ago
Subjects prescribed metformin or have taken metformin within 1 year.
Subjects with abnormal estimated glomerular filtration rate (eGFR).
Hypertriglyceridemic (>400 mg/dl) and hypercholesterolemic (>260 mg/dl) subjects
Hypertensive (>160/100 mmHg)
Subjects currently taking medications that affect heart rate and rhythm (i.e. Ca++channel blockers, nitrates, alpha- or beta-blockers).
Subjects with a history of significant metabolic, cardiac, congestive heart failure,cerebrovascular, hematological, pulmonary, gastrointestinal, liver, renal, orendocrine disease or cancer that in the investigator's opinion would interfere withor alter the outcome measures, or impact subject safety.
Pregnant (as evidenced by positive pregnancy test) or nursing women
Subjects with contraindications to participation in an exercise training program
Currently taking active weight suppression medication (e.g. phentermine,orlistat,lorcaserin, naltrexone-bupropion in combination, liraglutide, benzephetamine,diethylpropion, phendimetrazine)
Known hypersensitivity to perflutren (contained in Definity)
Study Design
Connect with a study center
Rutgers University Loree Gymnasium
New Brunswick, New Jersey 08901
United StatesSite Not Available
University of Virginia
Charlottesville, Virginia 22904
United StatesSite Not Available
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.